Disorderly Brexit May Necessitate Drug Airlifts, Sanofi UK Head Warns
Executive Summary
A badly planned British departure from the EU could make airlifting of drugs into the UK necessary to ensure adequate supplies are maintained, Sanofi’s managing director in the UK said.
You may also be interested in...
No-Deal Brexit 'Very Bad' For Business And Patients
Peter Martin, COO of Norgine, is concerned about the ‘mood music’ in the political environment in the UK, and warns about the risks of the UK leaving the EU without a deal in place.
EMA Chief Says Brexit Has Impaired Ability To Support R&D
The reduction in the European Medicines Agency’s activities since the UK voted to leave the EU nearly three years has impaired the regulator's ability to keep up with scientific and regulatory developments, and it is facing more staff losses as a result of its relocation to the Netherlands. However, the agency says it has managed to safeguard its core activities relating to the evaluation and supervision of medicines, and that the EU regulatory network should be able to adapt to Brexit-related changes without jeopardizing the quality of its work.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.